SCHEMBL4135850

SCHEMBL4135850

CC(C)[C@@H](O)[C@H](NC(=O)c1cc2ccccc2s1)C(=O)NCCCCNS(=O)(=O)c1ccc(F)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.50
BMP1 P13497 1/20 0.42
RAB9A P51151 1/20 0.41
CCR1 P32246 2/20 0.41
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
OPRM1 P35372 4/20 0.40
PIN1 Q13526 4/20 0.40
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
HDAC2 Q92769 1/20 0.37
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
DRD4 P21917 1/20 0.37
ADRA1D P25100 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4135852 1.00 TRPV4 (0.50) TRPV4BMP1RAB9ACCR1CTSB
SCHEMBL4133524 0.92 TRPV4 (0.48) TRPV4BMP1RAB9ACCR1CTSB
SCHEMBL4133530 0.92 TRPV4 (0.48) TRPV4BMP1RAB9ACCR1CTSB
SCHEMBL4147519 0.87 TRPV4 (0.66) TRPV4BMP1RAB9ACTSBCTSS
SCHEMBL4136338 0.85 TRPV4 (0.54) TRPV4BMP1RAB9ACTSBCTSS
SCHEMBL5434875 0.85 TRPV4 (0.66) TRPV4BMP1RAB9ACTSBCTSS
SCHEMBL4139617 0.85 TRPV4 (0.48) TRPV4BMP1RAB9ACTSBCTSS
SCHEMBL4135447 0.84 TRPV4 (0.57) TRPV4BMP1RAB9ACTSBCTSS
SCHEMBL13872662 0.83 TRPV4 (0.52) TRPV4
SCHEMBL4129737 0.83 TRPV4 (0.52) TRPV4BMP1RAB9ACTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US claimed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof SMITHKLINE BEECHAM CORPORATION 2009-04-23 US disclosed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105259-A1 Acyclic 1,4-Diamines and Uses Thereof TRPV4, TRPC4, TRPV1 TRPV4 1/4885BMP1 2172/4885RAB9A 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.